Drug safety
Vitruvias recalls 30-mg thyroid tablets over excessive potency
The FDA says the nationwide, ongoing Class I recall covers Vitruvias’ 30-mg thyroid tablets because they are superpotent.
The FDA classified Vitruvias Therapeutics’ recall of a lot of its levothyroxine-liothyronine Thyroid Tablets as Class I, its most serious recall classification, MedPage Today reported. The FDA’s recall record gives the reason as a superpotent drug.
The FDA record lists Thyroid Tablets, USP, 1/2 Grain (30 mg), with each tablet containing levothyroxine (T4) 19 mcg and liothyronine (T3) 4.5 mcg. The product is prescription-only and comes in bottles of 100 Tablets. The record says the products were distributed nationwide, the recall started 2026-08-21, and it was reported 2026-09-23. Its status is ongoing.
